Over the past two decades, new insights have positioned phosphoinositide 3-kinase-γ (PI3Kγ) as a context-dependent modulator of immunity and inflammation. Recent advances in protein structure determination and drug development have allowed for generation of highly specific PI3Kγ inhibitors, with the first now in clinical trials for several oncology indications. Recently, a monogenic immune disorder caused by PI3Kγ deficiency was discovered in humans and modelled in mice. Human inactivated PI3Kγ syndrome confirms the immunomodulatory roles of PI3Kγ and strengthens newly defined roles of this molecule in modulating inflammatory cytokine release in macrophages. Here, we review the functions of PI3Kγ in the immune system and discuss how our understanding of its potential as a therapeutic target has evolved.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bader, A. G., Kang, S., Zhao, L. & Vogt, P. K. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5, 921–929 (2005).
Vanhaesebroeck, B., Stephens, L. & Hawkins, P. PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13, 195–203 (2012).
Traynor-Kaplan, A. E., Harris, A. L., Thompson, B. L., Taylor, P. & Sklar, L. A. An inositol tetrakisphosphate-containing phospholipid in activated neutrophils. Nature 334, 353–356 (1988).
Hawkins, P. T., Jackson, T. R. & Stephens, L. R. Platelet-derived growth factor stimulates synthesis of PtdIns(3,4,5)P3 by activating a PtdIns(4,5)P2 3-OH kinase. Nature 358, 157–159 (1992).
Haslam, R. J., Koide, H. B. & Hemmings, B. A. Pleckstrin domain homology. Nature 363, 309–310 (1993).
Lemmon, M. A. & Ferguson, K. M. Molecular determinants in pleckstrin homology domains that allow specific recognition of phosphoinositides. Biochem. Soc. Trans. 29, 377–384 (2001).
Angulo, I. et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 342, 866–871 (2013).
Conley, M. E. et al. Agammaglobulinemia and absent B lineage cells in a patient lacking the p85alpha subunit of PI3K. J. Exp. Med. 209, 463–470 (2012).
Deau, M. C. et al. A human immunodeficiency caused by mutations in the PIK3R1 gene. J. Clin. Invest. 125, 1764–1765 (2015).
Lucas, C. L. et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat. Immunol. 15, 88–97 (2014).
Lucas, C. L. et al. Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. J. Exp. Med. 211, 2537–2547 (2014).
Takeda, A. J. et al. Human PI3Kgamma deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nat. Commun. 10, 4364 (2019).
Thian, M. et al. Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation. Haematologica https://doi.org/10.3324/haematol.2019.231399 (2020).
Burke, J. E. & Williams, R. L. Synergy in activating class I PI3Ks. Trends Biochem. Sci. 40, 88–100 (2015).
Wymann, M. P., Zvelebil, M. & Laffargue, M. Phosphoinositide 3-kinase signalling — which way to target? Trends Pharmacol. Sci. 24, 366–376 (2003).
Wymann, M. PI3Ks-drug targets in inflammation and cancer. Subcell. Biochem. 58, 111–181 (2012).
Suire, S., Hawkins, P. & Stephens, L. Activation of phosphoinositide 3-kinase gamma by Ras. Curr. Biol. 12, 1068–1075 (2002).
Vadas, O. et al. Molecular determinants of PI3Kgamma-mediated activation downstream of G-protein-coupled receptors (GPCRs). Proc. Natl Acad. Sci. USA 110, 18862–18867 (2013).
Schmid, M. C. et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715–727 (2011).
Pacold, M. E. et al. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell 103, 931–943 (2000).
Rubio, I. et al. Farnesylation of Ras is important for the interaction with phosphoinositide 3-kinase gamma. Eur. J. Biochem. 266, 70–82 (1999).
Luo, L. et al. Rab8a interacts directly with PI3Kgamma to modulate TLR4-driven PI3K and mTOR signalling. Nat. Commun. 5, 4407 (2014).
Wall, A. A. et al. Small GTPase Rab8a-recruited phosphatidylinositol 3-kinase gamma regulates signaling and cytokine outputs from endosomal toll-like receptors. J. Biol. Chem. 292, 4411–4422 (2017).
Luo, L. et al. TLR crosstalk activates LRP1 to recruit Rab8a and PI3Kgamma for suppression of inflammatory responses. Cell Rep. 24, 3033–3044 (2018).
Laffargue, M. et al. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 16, 441–451 (2002).
Walser, R. et al. PKCbeta phosphorylates PI3Kgamma to activate it and release it from GPCR control. PLoS Biol. 11, e1001587 (2013).
Maehama, T. & Dixon, J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375–13378 (1998).
Manning, B. D. & Toker, A. AKT/PKB signaling: navigating the network. Cell 169, 381–405 (2017).
Hsu, P. P. et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317–1322 (2011).
Weichhart, T., Hengstschlager, M. & Linke, M. Regulation of innate immune cell function by mTOR. Nat. Rev. Immunol. 15, 599–614 (2015).
Ivanov, S. S. & Roy, C. R. Pathogen signatures activate a ubiquitination pathway that modulates the function of the metabolic checkpoint kinase mTOR. Nat. Immunol. 14, 1219–1228 (2013).
Weichhart, T. et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29, 565–577 (2008).
Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 287, 1049–1053 (2000).
Li, Z. et al. Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science 287, 1046–1049 (2000).
Sasaki, T. et al. Function of PI3Kgamma in thymocyte development, T cell activation, and neutrophil migration. Science 287, 1040–1046 (2000).
Patrucco, E. et al. PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118, 375–387 (2004).
Del Prete, A. et al. Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J. 23, 3505–3515 (2004).
Camps, M. et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat. Med. 11, 936–943 (2005).
Ferguson, G. J. et al. PI(3)Kgamma has an important context-dependent role in neutrophil chemokinesis. Nat. Cell Biol. 9, 86–91 (2007).
Arcaro, A. & Wymann, M. P. Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses. Biochem. J. 296, 297–301 (1993).
Hannigan, M. et al. Neutrophils lacking phosphoinositide 3-kinase γ show loss of directionality during N-formyl-Met-Leu-Phe-induced chemotaxis. Proc. Natl Acad. Sci. USA 99, 3603–3608 (2002).
Van Keymeulen, A. et al. To stabilize neutrophil polarity, PIP3 and Cdc42 augment RhoA activity at the back as well as signals at the front. J. Cell Biol. 174, 437–445 (2006).
Andrews, S., Stephens, L. R. & Hawkins, P. T. PI3K class IB pathway in neutrophils. Sci. STKE https://doi.org/10.1126/stke.4072007cm3 (2007).
Condliffe, A. M. et al. Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106, 1432–1440 (2005).
Deladeriere, A. et al. The regulatory subunits of PI3Kgamma control distinct neutrophil responses. Sci. Signal. 8, ra8 (2015).
Hawkins, P. T. & Stephens, L. R. PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis. Science 318, 64–66 (2007).
Norton, L. et al. Localizing the lipid products of PI3Kgamma in neutrophils. Adv. Biol. Regul. 60, 36–45 (2016).
Bohnacker, T. et al. PI3Kgamma adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells. Sci. Signal. 2, ra27 (2009).
Nobs, S. P. et al. PI3-kinase-gamma has a distinct and essential role in lung-specific dendritic cell development. Immunity 43, 674–689 (2015).
Foukas, L. C. et al. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366–370 (2006).
Ciraolo, E. et al. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 1, ra3 (2008).
Czech, M. P. Insulin action and resistance in obesity and type 2 diabetes. Nat. Med. 23, 804–814 (2017).
Haeusler, R. A., McGraw, T. E. & Accili, D. Biochemical and cellular properties of insulin receptor signalling. Nat. Rev. Mol. Cell Biol. 19, 31–44 (2018).
Molinaro, A. et al. Insulin-driven PI3K-AKT signaling in the hepatocyte is mediated by redundant PI3Kalpha and PI3Kbeta activities and is promoted by RAS. Cell Metab. 29, 1400–1409.e5 (2019).
Becattini, B. et al. PI3Kgamma within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance. Proc. Natl Acad. Sci. USA 108, E854–E863 (2011).
Kobayashi, N. et al. Blockade of class IB phosphoinositide-3 kinase ameliorates obesity-induced inflammation and insulin resistance. Proc. Natl Acad. Sci. USA 108, 5753–5758 (2011).
Breasson, L. et al. PI3Kgamma activity in leukocytes promotes adipose tissue inflammation and early-onset insulin resistance during obesity. Sci. Signal. https://doi.org/10.1126/scisignal.aaf2969 (2017).
Wymann, M. P. & Solinas, G. Inhibition of phosphoinositide 3-kinase gamma attenuates inflammation, obesity, and cardiovascular risk factors. Ann. N. Y. Acad. Sci. 1280, 44–47 (2013).
Kachele, M. et al. Variation in the phosphoinositide 3-kinase gamma gene affects plasma HDL-cholesterol without modification of metabolic or inflammatory markers. PLoS One 10, E0144494 (2015).
Vinnikov, I. A. et al. Hypothalamic miR-103 protects from hyperphagic obesity in mice. J. Neurosci. 34, 10659–10674 (2014).
Galkina, E. & Ley, K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu. Rev. Immunol. 34, 165–197 (2009).
Gistera, A. & Hansson, G. K. The immunology of atherosclerosis. Nat. Rev. Nephrol. 13, 368–380 (2017).
Saigusa, R., Winkels, H. & Ley, K. T cell subsets and functions in atherosclerosis. Nat. Rev. Cardiol. 17, 387–401 (2020).
Chang, J. D. et al. Deletion of the phosphoinositide 3-kinase p110gamma gene attenuates murine atherosclerosis. Proc. Natl Acad. Sci. USA 104, 8077–8082 (2007).
Fougerat, A. et al. Genetic and pharmacological targeting of phosphoinositide 3-kinase-gamma reduces atherosclerosis and favors plaque stability by modulating inflammatory processes. Circulation 117, 1310–1317 (2008).
Zotes, T. M. et al. PI3K p110gamma deletion attenuates murine atherosclerosis by reducing macrophage proliferation but not polarization or apoptosis in lesions. PLoS One 8, e72674 (2013).
Viard, P. et al. Gbetagamma dimers stimulate vascular L-type Ca2+ channels via phosphoinositide 3-kinase. FASEB J. 13, 685–694 (1999).
Quignard, J. F. et al. Phosphoinositide 3-kinase gamma mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. J. Biol. Chem. 276, 32545–32551 (2001).
Vecchione, C. et al. Protection from angiotensin II-mediated vasculotoxic and hypertensive response in mice lacking PI3Kgamma. J. Exp. Med. 201, 1217–1228 (2005).
Carnevale, D. et al. PI3Kgamma inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism. Cardiovasc. Res. 93, 200–209 (2012).
Perrotta, M., Lembo, G. & Carnevale, D. The multifaceted roles of PI3Kgamma in hypertension, vascular biology, and inflammation. Int. J. Mol. Sci. https://doi.org/10.3390/ijms17111858 (2016).
Smirnova, N. F. et al. Targeting PI3Kgamma activity decreases vascular trauma-induced intimal hyperplasia through modulation of the Th1 response. J. Exp. Med. 211, 1779–1792 (2014).
Yu, Q. et al. PI3Kgamma (phosphoinositide 3-kinase gamma) regulates vascular smooth muscle cell phenotypic modulation and neointimal formation through CREB (cyclic AMP-response element binding protein)/YAP (yes-associated protein) signaling. Arterioscler. Thromb. Vasc. Biol. 39, e91–e105 (2019).
Perino, A. et al. Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110gamma. Mol. Cell 42, 84–95 (2011).
Ban, K. et al. Phosphatidylinositol 3-kinase gamma is a critical mediator of myocardial ischemic and adenosine-mediated preconditioning. Circ. Res. 103, 643–653 (2008).
Haubner, B. J. et al. PI3Kgamma protects from myocardial ischemia and reperfusion injury through a kinase-independent pathway. PLoS One 5, e9350 (2010).
Nienaber, J. J. et al. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. J. Clin. Invest. 112, 1067–1079 (2003).
Doukas, J. et al. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proc. Natl Acad. Sci. USA 103, 19866–19871 (2006).
Rommel, C., Camps, M. & Ji, H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol. 7, 191–201 (2007).
Barber, D. F. et al. PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus. Nat. Med. 11, 933–935 (2005).
Webb, L. M., Vigorito, E., Wymann, M. P., Hirsch, E. & Turner, M. Cutting edge: T cell development requires the combined activities of the p110gamma and p110delta catalytic isoforms of phosphatidylinositol 3-kinase. J. Immunol. 175, 2783–2787 (2005).
Ali, K. et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407–411 (2014).
Swan, D. J. et al. Immunodeficiency, autoimmune thrombocytopenia and enterocolitis caused by autosomal recessive deficiency of PIK3CD-encoded phosphoinositide 3-kinase delta. Haematologica 104, e483–e486 (2019).
De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539, 443–447 (2016).
Kaneda, M. M. et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
Beura, L. K. et al. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532, 512–516 (2016).
Reese, T. A. et al. Sequential infection with common pathogens promotes human-like immune gene expression and altered vaccine response. Cell Host Microbe 19, 713–719 (2016).
Gangadhara, G. et al. A class of highly selective inhibitors bind to an active state of PI3Kgamma. Nat. Chem. Biol. 15, 348–357 (2019).
Bergamini, G. et al. A selective inhibitor reveals PI3Kgamma dependence of T(H)17 cell differentiation. Nat. Chem. Biol. 8, 576–582 (2012).
Pemberton, N. et al. Discovery of highly isoform selective orally bioavailable phosphoinositide 3-Kinase (PI3K)-gamma inhibitors. J. Med. Chem. 61, 5435–5441 (2018).
Collier, P. N. et al. Discovery of highly isoform selective thiazolopiperidine inhibitors of phosphoinositide 3-Kinase gamma. J. Med. Chem. 58, 5684–5688 (2015).
Evans, C. A. et al. Discovery of a selective phosphoinositide-3-kinase (PI3K)-gamma inhibitor (IPI-549) as an immuno-oncology clinical candidate. ACS Med. Chem. Lett. 7, 862–867 (2016).
Rathinaswamy, M. K. et al. Disease-related mutations in PI3Kgamma disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. eLife https://doi.org/10.7554/eLife.64691 (2021).
Alessi, D. R. et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr. Biol. 7, 261–269 (1997).
Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098–1101 (2005).
Kurig, B. et al. Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma. Proc. Natl Acad. Sci. USA 106, 20312–20317 (2009).
Sullivan, R. J. et al. Initial results from first-in-human study of IPI-549, a tumor macrophage-targeting agent, combined with nivolumab in advanced solid tumors. J. Clin. Oncol. 36, 3013–3013 (2018).
Janku, F., Yap, T. A. & Meric-Bernstam, F. Targeting the PI3K pathway in cancer: are we making headway? Nat. Rev. Clin. Oncol. 15, 273–291 (2018).
Schmid, M. C. et al. PI3-kinase gamma promotes Rap1a-mediated activation of myeloid cell integrin alpha4beta1, leading to tumor inflammation and growth. PLoS One 8, e60226 (2013).
Kaneda, M. M. et al. Macrophage PI3Kgamma drives pancreatic ductal adenocarcinoma progression. Cancer Discov. 6, 870–885 (2016).
Foubert, P., Kaneda, M. M. & Varner, J. A. PI3Kgamma activates integrin alpha4 and promotes immune suppressive myeloid cell polarization during tumor progression. Cancer Immunol. Res. 5, 957–968 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03719326 (2018).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03980041 (2019).
Postow, M. et al. 434 Updated clinical data from the melanoma expansion cohort of an ongoing Ph1/1b Study of eganelisib (formerly IPI-549) in combination with nivolumab. J. Immunother. Cancer 8, A264–A265 (2020).
Tomczak, P. et al. Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma. J. Clin. Oncol. 39, 436–436 (2021).
Ladygina, N. et al. PI3Kgamma kinase activity is required for optimal T-cell activation and differentiation. Eur. J. Immunol. 43, 3183–3196 (2013).
Hirsch, E. et al. Resistance to thromboembolism in PI3Kgamma-deficient mice. FASEB J. 15, 2019–2021 (2001).
Lian, L. et al. The relative role of PLCbeta and PI3Kgamma in platelet activation. Blood 106, 110–117 (2005).
Moore, S. F., Smith, N. R., Blair, T. A., Durrant, T. N. & Hers, I. Critical roles for the phosphatidylinositide 3-kinase isoforms p110beta and p110gamma in thrombopoietin-mediated priming of platelet function. Sci. Rep. 9, 1468 (2019).
Crackower, M. A. et al. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 110, 737–749 (2002).
Siragusa, M. et al. Involvement of phosphoinositide 3-kinase gamma in angiogenesis and healing of experimental myocardial infarction in mice. Circ. Res. 106, 757–768 (2010).
Seropian, I. M. et al. Pharmacologic inhibition of phosphoinositide 3-kinase gamma (PI3Kgamma) promotes infarct resorption and prevents adverse cardiac remodeling after myocardial infarction in mice. J. Cardiovasc. Pharmacol. 56, 651–658 (2010).
Lupia, E. et al. Ablation of phosphoinositide 3-kinase-gamma reduces the severity of acute pancreatitis. Am. J. Pathol. 165, 2003–2011 (2004).
Endo, D. et al. PI3Kgamma differentially regulates FcepsilonRI-mediated degranulation and migration of mast cells by and toward antigen. Int. Arch. Allergy Immunol. 149, 66–72 (2009).
Collmann, E. et al. Transient targeting of phosphoinositide 3-kinase acts as a roadblock in mast cells’ route to allergy. J. Allergy Clin. Immunol. 132, 959–968 (2013).
Takeda, M. et al. Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase gamma-deficient mice. J. Allergy Clin. Immunol. 123, 805–812 (2009).
Doukas, J. et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J. Pharmacol. 328, 758–765 (2009).
Winkler, D. G. et al. PI3K-delta and PI3K-gamma inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20, 1364–1374 (2013).
Sadiq, M. W. et al. Safety, tolerability and pharmacokinetics (PK) of AZD8154 (a selective PI3K?d inhibitor) after single ascending inhaled doses in healthy volunteers. Eur. Respir. J. 54, PA4220 (2019).
Perry, M. W. D. et al. Discovery of AZD8154, a dual PI3Kgammadelta inhibitor for the treatment of asthma. J. Med. Chem. 64, 8053–8075 (2021).
Harris, S. J. et al. Genetic ablation of PI3Kgamma results in defective IL-17RA signalling in T lymphocytes and increased IL-17 levels. Eur. J. Immunol. 42, 3394–3404 (2012).
Hayer, S. et al. PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. FASEB J. 23, 4288–4298 (2009).
Li, H. et al. PI3Kgamma inhibition alleviates symptoms and increases axon number in experimental autoimmune encephalomyelitis mice. Neuroscience 253, 89–99 (2013).
Rodrigues, D. H. et al. Absence of PI3Kgamma leads to increased leukocyte apoptosis and diminished severity of experimental autoimmune encephalomyelitis. J. Neuroimmunol. 222, 90–94 (2010).
Comerford, I., Litchfield, W., Kara, E. & McColl, S. R. PI3Kgamma drives priming and survival of autoreactive CD4+ T cells during experimental autoimmune encephalomyelitis. PLoS One 7, e45095 (2012).
Collier, P. N. et al. Structural basis for isoform selectivity in a class of benzothiazole inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 58, 517–521 (2015).
Come, J. H. et al. Design and synthesis of a novel series of orally bioavailable, CNS-penetrant, isoform selective phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors with potential for the treatment of multiple sclerosis (MS). J. Med. Chem. 61, 5245–5256 (2018).
Davids, M. S. et al. Efficacy and safety of duvelisib following disease progression on ofatumumab in patients with relapsed/refractory CLL or SLL in the DUO Crossover Extension Study. Clin. Cancer Res. 26, 2096–2103 (2020).
Pomel, V. et al. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma. J. Med. Chem. 49, 3857–3871 (2006).
Bell, K. et al. SAR studies around a series of triazolopyridines as potent and selective PI3Kgamma inhibitors. Bioorg. Med. Chem. Lett. 22, 5257–5263 (2012).
Blair, H. A. Duvelisib: first global approval. Drugs 78, 1847–1853 (2018).
Bruce, I. et al. Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway. Bioorg. Med. Chem. Lett. 22, 5445–5450 (2012).
Rathinaswamy, M. K. & Burke, J. E. Class I phosphoinositide 3-kinase (PI3K) regulatory subunits and their roles in signaling and disease. Adv. Biol. Regul. https://doi.org/10.1016/j.jbior.2019.100657 (2019).
Marone, R., Cmiljanovic, V., Giese, B. & Wymann, M. P. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim. Biophys. Acta 1784, 159–185 (2008).
Venable, J. D., Ameriks, M. K., Blevitt, J. M., Thurmond, R. L. & Fung-Leung, W. P. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease. Recent Pat. Inflamm. Allergy Drug Discov. 4, 1–15 (2010).
Stephens, L. R. et al. The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. Cell 89, 105–114 (1997).
Suire, S. et al. p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr. Biol. 15, 566–570 (2005).
Wymann, M. P. & Marone, R. Phosphoinositide 3-kinase in disease: timing, location, and scaffolding. Curr. Opin. Cell Biol. 17, 141–149 (2005).
Liu, P. et al. PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex. Cancer Discov. 5, 1194–1209 (2015).
Yuan, H. X. & Guan, K. L. The SIN1-PH domain connects mTORC2 to PI3K. Cancer Discov. 5, 1127–1129 (2015).
Andreotti, A. H., Joseph, R. E., Conley, J. M., Iwasa, J. & Berg, L. J. Multidomain control over TEC kinase activation state tunes the T cell response. Annu. Rev. Immunol. 36, 549–578 (2018).
Walker, E. H. et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909–919 (2000).
Anzinger, J. J. et al. Murine bone marrow-derived macrophages differentiated with GM-CSF become foam cells by PI3Kgamma-dependent fluid-phase pinocytosis of native LDL. J. Lipid Res. 53, 34–42 (2012).
Mosser, D. M. & Edwards, J. P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958–969 (2008).
Lova, P. et al. A selective role for phosphatidylinositol 3,4,5-trisphosphate in the Gi-dependent activation of platelet Rap1B. J. Biol. Chem. 278, 131–138 (2003).
Cosemans, J. M. et al. Continuous signaling via PI3K isoforms beta and gamma is required for platelet ADP receptor function in dynamic thrombus stabilization. Blood 108, 3045–3052 (2006).
Canobbio, I. et al. Genetic evidence for a predominant role of PI3Kbeta catalytic activity in ITAM- and integrin-mediated signaling in platelets. Blood 114, 2193–2196 (2009).
Suire, S. et al. Gbetagammas and the Ras binding domain of p110gamma are both important regulators of PI(3)Kgamma signalling in neutrophils. Nat. Cell Biol. 8, 1303–1309 (2006).
Tang, W. et al. A PLCbeta/PI3Kgamma-GSK3 signaling pathway regulates cofilin phosphatase slingshot2 and neutrophil polarization and chemotaxis. Dev. Cell 21, 1038–1050 (2011).
Weiss-Haljiti, C. et al. Involvement of phosphoinositide 3-kinase gamma, Rac, and PAK signaling in chemokine-induced macrophage migration. J. Biol. Chem. 279, 43273–43284 (2004).
Nobs, S. P. et al. PI3Kgamma is critical for dendritic cell-mediated CD8+ T cell priming and viral clearance during influenza virus infection. PLoS Pathog. 12, e1005508 (2016).
Wymann, M. P. et al. Phosphoinositide 3-kinase gamma: a key modulator in inflammation and allergy. Biochem. Soc. Trans. 31, 275–280 (2003).
Kurig, B. et al. Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110γ. Proc. Natl Acad. Sci. USA 106, 20312–20317 (2009).
Tassi, I. et al. p110gamma and p110delta phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity 27, 214–227 (2007).
Saudemont, A. et al. p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc. Natl Acad. Sci. USA 106, 5795–5800 (2009).
Martin, A. L., Schwartz, M. D., Jameson, S. C. & Shimizu, Y. Selective regulation of CD8 effector T cell migration by the p110gamma isoform of phosphatidylinositol 3-kinase. J. Immunol. 180, 2081–2088 (2008).
Thomas, M. S., Mitchell, J. S., DeNucci, C. C., Martin, A. L. & Shimizu, Y. The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J. Leukoc. Biol. 84, 814–823 (2008).
Garcia, C. C. et al. Phosphatidyl Inositol 3 kinase-gamma balances antiviral and inflammatory responses during influenza A H1N1 infection: from murine model to genetic association in patients. Front. Immunol. 9, 975 (2018).
Huang, X. et al. Endothelial p110gammaPI3K mediates endothelial regeneration and vascular repair after inflammatory vascular injury. Circulation 133, 1093–1103 (2016).
Nombela-Arrieta, C. et al. Differential requirements for DOCK2 and phosphoinositide-3-kinase gamma during T and B lymphocyte homing. Immunity 21, 429–441 (2004).
Beer-Hammer, S. et al. The catalytic PI3K isoforms p110gamma and p110delta contribute to B cell development and maintenance, transformation, and proliferation. J. Leukoc. Biol. 87, 1083–1095 (2010).
Silva, M. C. et al. Canonical PI3Kgamma signaling in myeloid cells restricts Trypanosoma cruzi infection and dampens chagasic myocarditis. Nat. Commun. 9, 1513 (2018).
C.L.L. acknowledges funding from the National Institutes of Health (NIAID R21AI144315) and Mathers Foundation. The authors thank K. Jones for her helpful comments on their manuscript. M.P.W. was funded by the Swiss National Science Foundation (grants SNF 316030_198526 and 310030_189065), Innosuisse (grant 37213.1 IP-LS) and the Horizon 2020 project ITN 675392.
The authors declare no competing interests.
Peer review information
Nature Reviews Immunology thanks David Fruman and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Primary immunodeficiency disorder
One of a collection of distinct rare disorders resulting from a gene defect that causes dysfunctional immune responses and recurrent infection.
- Fatty streaks
Disintegrated foam cells (fat-loaded macrophages) that form a layer of fat beneath endothelial cells and disengage them from the extracellular matrix.
Production of (body) heat by short-circuiting mitochondria, for example, with uncoupling proteins.
- Foam cells
Macrophages that has consumed degraded LDL particles and has a microscopic appearance of foam.
An oral and selective next-generation PI3Kγ inhibitor developed by Infinity Pharmaceuticals.
About this article
Cite this article
Lanahan, S.M., Wymann, M.P. & Lucas, C.L. The role of PI3Kγ in the immune system: new insights and translational implications. Nat Rev Immunol 22, 687–700 (2022). https://doi.org/10.1038/s41577-022-00701-8
This article is cited by
PI3Kγ controls IL-17A expression and attenuates alveolar bone loss in an experimental periodontitis model
Inflammation Research (2022)